Tag Archives | Alzheimer Disease

Life Science News Update:$700M in Fed Research Center at NIH; AD Diagnosis

Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines – NYTimes.com Most experts believe the PET Imaging procedure can be helpful. Alzheimer’s Scan Might Help Spot Disease Alzheimer’s Association […]

Continue Reading 0

Medivation hangover -stock stable

Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama: Robert Langreth writing in Forbes offers the potential of better results on two upcoming trials and comments from Lon Schneider, an […]

Continue Reading 0

Medivation Chills Biotech Sector

Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint release Medivation and its partner Pfizer (PFE) said its two Phase III trials […]

Continue Reading 0